ReviewThe oncologist2021
Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms.
Review in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Longitudinal Neurocognitive Changes for Patients With Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review With Structured Narrative Synthesis.European journal of haematology · 2026Pooled it
- Treatment-related neuroanatomical and functional consequences of hematopoietic stem cell transplantation: A comprehensive review of brain structure and function.Chinese medical journal · 2026Review
- Quality of Life in CAR-T Cell Therapy.Hematology reports · 2026Review
- Neuropsychiatric-pharmacologic synergy: interaction between psychiatric polypharmacy and cancer treatment-related neurotoxicity.Oxford medical case reports · 2026Article
- Psychological Prehabilitation for People Undergoing Autologous Stem Cell Transplant: A Qualitative Study.Psycho-oncology · 2026Article
- Symptom clusters and sentinel symptoms during post-transplant recovery in recipients of allogeneic hematopoietic stem cell transplantation: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2025Article
- Risk for neurocognitive impairment in Korean childhood cancer survivors.Scientific reports · 2025Article
- Assessing cognitive function in transplantation and chimeric antigen receptor t cell therapy recipients: Expert recommendations from the survivorship, aging and biobehavioral special interest groups of the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2025Review
- Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia.Blood immunology & cellular therapy · 2025Article
- Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment.Journal of cancer survivorship : research and practice · 2025Article
- Long-term patient-reported outcomes following allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2025Article
- Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies.Transplantation and cellular therapy · 2025Article
- Predictive risk model of mild cognitive impairment in patients with malignant haematological diseases after haematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.Bone marrow transplantation · 2024Article
- Cancer related cognitive impairment: a downside of cancer treatment.Frontiers in oncology · 2024Review
- Long-term neurocognitive effects of chimeric antigen receptor T-cell therapy: Integrating assessments into nursing practice.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2024Article
- Article
- Managing Survivorship after Hematopoietic Cell Transplantation.Current hematologic malignancy reports · 2023Review
- Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation.Transplantation and cellular therapy · 2023Article
- Neuroimaging and Neurocognitive Outcomes in Older Patients with Multiple Myeloma Treated with Chemotherapy and Autologous Stem Cell Transplantation.Research square · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Hematopoietic stem cell transplant (HSCT) plays a central role in the treatment of hematologic cancers. With the increasing survival of patients after HSCT, survivorship issues experienced by this population have become an important outcome. Cognitive impairment is an established sequela of HSCT, with studies to date establishing its presence, associated risk factors, and clinical phenotype. There are multiple potential contributors to cognitive impairment after HSCT. Efforts are ongoing to further characterize its clinical phenotype, associated biomarkers, and biologic underpinnings. A fundamental knowledge of post-HSCT cognitive impairment is of value for all clinicians who interface with this population, and further academic efforts are needed to more fully understand the impact of this cancer treatment on brain health. IMPLICATIONS FOR PRACTICE: As survival outcomes after hematopoietic stem cell transplant (HSCT) improve, an awareness of the post-treatment challenges faced by this population has become central to its care. HSCT can have a sustained and broad impact on brain health, causing cognitive dysfunction, fatigue, disturbed mood, and sleep. In affected patients, autonomy, return to work, relationships, and quality of life may all be affected. A fundamental fluency in this area is important for clinicians interfacing with HSCT survivors, facilitating the identification and management of cognitive dysfunction and concurrent symptom clusters, and stimulating interest in these sequelae as areas for future clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.